[Imatinib and solid tumours].
Imatinib mesylate (Gleevec, Glivec, Novartis, Basel, Switzerland) is a small molecule inhibitor of the tyrosine kinase c-abl, c-kit and the platelet derived growth factor receptor (PDGFR). Imatinib was developed for the treatment of chronic myeloid leukaemia (CML) but was approved both in Europe and the US fro the treatment of CML and gastrointestinal stromal tumors (GIST). Given its activity against both c-kit and PDGFR kinases and its remarkable safety profile, imatinib has been 'tried' in several solid tumors; results however have often been deceiving. We review the current data regarding the activity of imatinib in solid tumors, including GIST.
Arifi
Samia
S
Unité de jour d'oncologie médicale multidisciplinaire, pavillon E, Hôpital Edouard-Herriot, 5 place d'Arsonval, 69003 Lyon, France.
El Sayadi
Hiba
H
Dufresne
Armelle
A
Ray-Coquard
Isabelle
I
Fayette
Jérôme
J
Méeus
Pierre
P
Ranchère
Dominique
D
Decouvelaere
Anne-Valérie
AV
Alberti
Laurent
L
Tabone-Eglinger
Séverine
S
Blay
Jean-Yves
JY
Cassier
Philippe
P
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000188:drug therapy; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D012878:Skin Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl